Wohlrab, Martin
Klenk, Jochen
Delgado-Ortiz, Laura
Chambers, Michael
Rochester, Lynn
Zuchowski, Matthias
Schwab, Matthias
Becker, Clemens
Jaeger, Simon U.
Funding for this research was provided by:
Innovative Medicines Initiative (820820)
Article History
Received: 15 July 2022
Accepted: 3 December 2022
First Online: 29 December 2022
Declarations
:
: Not applicable.
: Not applicable.
: MW reports grants from HORIZON 2020 IMI No. 820820, during the conduct of the study. SJ is partly supported by the Robert Bosch Stiftung Stuttgart. J.K. reports grants from HORIZON2020 IMI No.820820, during the conduct of the study. M.C. reports personal fees from Takeda Pharmaceuticals, during the conduct of the study; personal fees from Takeda Pharmaceuticals, outside the submitted work. MS is supported by the Robert Bosch Stiftung Stuttgart and reports grants from HORIZON 2020 IMI 2 Mobilise-D, during the conduct of the study, and grants and non-financial support from Green Cross WellBeing Co. Ltd., Gilead Sciences Inc., Robert Bosch GmbH, and CORAT Therapeutics GmbH, as well as other from Agena Bioscience GmbH, outside the submitted work. CB disclosed consultation fees from E. Lilly and speaker fees from Amgen, Nutricia and Pfizer, and reports grants from HORIZON 2020 IMI No. 820820, during the conduct of the study. LR reports grants from HORIZON2020 IMI 2 Mobilise-D and IDEA-FAST, National Institute for Health Research, Medical Research Council, Dunhill Medical Trust, Parkinson’s UK, and Cure Parkinson’s Trust.